Pharma News

The U.S. Food and Drug Administration (FDA) has approved Novartis’ Rhapsido® (remibrutinib) for adults with symptomatic dermographism (SD) whose symptoms are not adequately controlled with H1 antihistamines, making it the first FDA-approved treatment specifically for the condition.

Nova Biomedical has initiated a global medical device correction for its StatStrip Glucose Hospital Meter System after identifying a software issue that could cause a glucose test result to be associated with the wrong patient's medical record. The U.S. Food and Drug Administration (FDA) published the company's safety announcement on October 6, 2026.

A team from Flinders University’s Biomedical Nanoengineering Laboratory has found that vanillin has pronounced antioxidant, anti-inflammatory and antibacterial properties, making it a good candidate for wound-healing formulations.

AstraZeneca has completed its 2 billion USD equity investment in Summit Therapeutics, strengthening a strategic partnership focused on advancing ivonescimab, a potential first-in-class bispecific antibody targeting PD-1 and VEGF, in combination with antibody-drug conjugates (ADCs) across multiple cancer types.

Zydus Lifesciences Limited, in partnership with MSN Laboratories Private Limited, has launched Riociguat Tablets in the United States, becoming the first companies to market a generic version of Bayer’s Adempas® (riociguat) in the country.

The Drugs Consultative Committee (DCC) has proposed a prominent statutory warning on cough syrup labels restricting their use in children below four years of age, amid concerns over the widespread prescribing of cough syrups to young children.